18F-FDG PET/CT imaging in oncology

Annals of Saudi Medicine

Volumn 31, Issue 1, 2011, Pages 3-13

  Almuhaideb, Ahmad ^a   Papathanasiou, Nikolaos ^a   Bomanji, Jamshed ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LUNG CANCER; LUNG NODULE; LYMPHOMA; MELANOMA; ONCOLOGY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME; UTERINE CERVIX CANCER; METHODOLOGY; NEOPLASM; RADIOGRAPHY; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79251646358     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.75771     Document Type: Review

References (134)

1. Yang SK, Cho N, Moon WK. The role of PET/CT for evaluating breast cancer. Korean J Radiol 2007;8:429-37.
2. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 2000;18:3495-502.
3. Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med 2001;28:351-8.
4. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D- glucosepositron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 2001;93:630-5.
5. Benard F, Turcotte E. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res 2005;7:153-62.
6. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84-99.
7. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J cancer Res Clin Oncol 2003;129:147-53.
8. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18) F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
9. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88.
10. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-50.
11. De Geus-Oei L F, Ruers TJ, Punt CJ, Leer JW, Corstens FH, Oyen WJ. FDG-PET in colorectal cancer. Cancer Imaging 2006;6: S71-81.
12. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006;33:779-84.
13. Chessin DB, Kiran RP, Akhurst T, Guillem JG. The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer. J Am Coll Surg 2005;201:948-56.
14. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20.
15. Moore HG, Akhurst T, Larson SM, Minsky BD, Mazumdar M, Guillem JG. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003;197:22-8.
16. Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004;232:815-22.
17. Esteves F P, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: An overview. Semin Nucl Med 2006;36:169-81.
18. Liu FY, Chen JS, Changchien CR, Yeh CY, Liu SH, Ho KC, et al. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum 2005;48:1900-12.
19. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-7.
20. Engaras B. Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity. Dis Colon Rectum 2003;46:313-21.
21. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-9.
22. Blokhuis TJ, van der Schaaf MC, van den Tol M P, Comans EF, Manoliu RA, van der Sijp JR. Results of radio frequency ablation of primary and secondary liver tumors: Long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol Suppl 2004;241:93-7.
23. Simó M, Lomeña F, Setoain J, Pérez G, Castellucci P, Costansa JM, et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 2002;23:975-82.
24. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-63.
25. Bassi MC, Turri L, Sacchetti G, Loi G, Cannillo B, La Mattina P, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1423-6.
26. Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 2007;65:377-84.
27. Zhang X, Watson DI, Lally C, Bessell JR. Endoscopic ultrasound for preoperative staging of esophageal carcinoma. Surg Endosc 2005;19:1618-21.
28. ASGE Standards of Practice Committee, Gan SI, Rajan E, Adler DG, Baron TH, Anderson MA, et al. Role of EUS. Gastrointest Endosc 2007;66:425-34.
29. Yang GY, Wagner TD, Jobe BA, Thomas CR. The role of positron emission tomography in esophageal cancer. Gastrointest Cancer Res 2008;2:3-9.
30. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005;103:148-56.
31. Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808-15.
32. Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003;227:764-70.
33. Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133-6.
34. Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with (18) F-FDG PET. J Nucl Med 2004;45:980-7.
35. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-10.
36. van Westreenen HL, Westerterp M, Jager PL, van Dullemen HM, Sloof GW, Comans EF, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med 2005;46:1321-5.
37. Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 2001;233:300-9. (Pubitemid 32187807)
38. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 2005;326:841-51.
39. Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G, et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1123-8.
40. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FDG-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269-75.
41. Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005;63:340-5.
42. Flamen P, Lerut A, Van Cutsem E, Cambier J P, Maes A, De Wever W, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000;120:1085-92.
43. Fleming AJ Jr, Johansen ME. The clinician's expectations from the use of positron emission tomography/computed tomography scanning in untreated and treated head and neck cancer patients. Curr Opin Otolaryngol Head Neck Surg 2008;16:127-34.
44. Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis LW. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 2005;27:494-502.
45. Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, et al. Initial experience of FDG-PET/CT guided IMRT of head-andneck carcinoma. Int J Radiat Oncol Biol Phys 2006;65:143-51.
46. Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007;117:1173-9.
47. Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: Impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg 2007;137:130-7.
48. Yamamoto Y, Wong T, Turkington T, Hawk T, Coleman R. Head and neck cancer: Dedicated FDG PET/CT protocol for detection-phantom and initial clinical studies. Radiology 2007;244:263-72.
49. Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2- fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 2005;115:1186-90.
50. Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007;29:986-95.
51. Deantonio L, Beldì D, Gambaro G, Loi G, Brambilla M, Inglese E, et al. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008;3:29.
52. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;61:129-36.
53. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52. (Pubitemid 38580197)
54. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
55. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: A comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol 2007;62:199-204.
56. Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:322-9.
57. Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006;65:1315-22.
58. Miele E, Spinelli G P, Tomao F, Zullo A, De Marinis F, Pasciuti G, et al. Positron emission tomography (PET) radiotracers in oncology-utility of 18F-fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res 2008;27:52.
59. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of nonsmall cell lung cancer: The guidelines. Chest 2003;123:147S-56.
60. Diva F, Oliveira A, Barroso A, Conde S, Parente B. Positron emission tomography: Indications in lung cancer - a prospective experience. Rev Port Pneumol 2005;11:12-3.
61. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000;117:773-8.
62. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
63. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. 18F-18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radiochemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463-71.
64. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with PET-CT. N Eng J Med 2009;361:32-9.
65. Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, et al. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441-6.
66. Marom EM, McAdams H P, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-9
67. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A metaanalysis. Ann Intern Med 2003;139:879-92.
68. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-9.
69. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
70. Verhagen AF, Bootsma G P, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: How does it change the algorithm?. Lung cancer 2004;44:175-81.
71. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-9.
72. Jett JR. How to optimize staging in early nonsmall cell lung cancer. Lung cancer 2002;38: S13-6.
73. Kramer H, Groen HJ. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Surg 2003;238:180-8.
74. Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E, et al. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 2008;33:104-9. (Pubitemid 350266343)
75. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-92.
76. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging nonsmall cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-81.
77. De Ruysscher D, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Utama I, Simons J, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-smallcell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-94.
78. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact of FDG-PET on radiation therapy volume delineation in nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86.
79. van Loon J, Offermann C, Bosmans G, Wanders R, Dekker A, Borger J, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: A planning study. Radiother Oncol 2008;87:49-54.
80. Joshi SC, Pant I, Hamzah F, Kumar G, Shukla AN. Integrated positron emission tomography/computed tomography fusion imaging: An emerging gold standard in lung cancer. Indian J Cancer 2008;45:137-41.
81. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W, et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung cancer 1998;19:167-77.
82. Mac Manus MP, Hicks RJ. PET scanning in lung cancer: Current status and future directions. Semin Surg Oncol 2003;21:149-55.
83. Hellwig D, Gröschel A, Graeter T P, Hellwig A P, Nestle U, Schäfers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21.
84. Rohren EM, Lowe VJ. Update in PET imaging of nonsmall cell lung cancer. Semin Nucl Med 2004;34:134-53.
85. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of nonsmall cell lung cancer. Eur J radiol 2003;45:49-59.
86. Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376-80.
87. Hellwig D, Gröschel A, Graeter T P, Hellwig A P, Nestle U, Schäfers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21.
88. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. The utility of (18) F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001;42:1605-13.
89. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-9.
90. Lowe V, Naunheim K. Positron emission tomography in lung cancer. Ann Thorac Surg 1998;65:1821-9.
91. Behzadi A, Ung Y, Lowe V, Deschamps C. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg 2009;52:235-42.
92. Fletcher JW, Kymes SM, Gould M, Alazraki N, Coleman RE, Lowe VJ. et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008;49:179-85.
93. Dhanapathi H, Kumar R. F-18 FDG PET/PET-CT in the management of lymphoma. Indian J Med Pediatr Oncol 2007;28:17-23.
94. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
95. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8.
96. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging: Do we need contrast-enhanced CT? Radiology 2004;232:823-89.
97. Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185-9.
98. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-51.
99. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 2007;7:10-8.
100. Joe A, Hoegerle S, Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med 2001;26:542-3.
101. Taaleb K, Kaiser K P, Wieler H. Elevated uptake of F-18 FDG in PET scans in nonmalignant disease. Clin Nucl Med 2000;25:939-40.
102. Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, et al. Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001;12:719-22.
103. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-63.
104. Talbot JN, Haioun C, Rain JD, Meignan M, Wioland M, Misset JL, et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001;38:193-221.
105. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9.
106. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-8.
107. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52.
108. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23.
109. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81.
110. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
111. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639-45.
112. Horn J, Lock-Andersen J, Sjostrand H, Loft A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006;33:887-92.
113. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
114. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115:237-43.
115. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24.
116. Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: What is the impact of each modality?. Eur J Nucl Med Mol Imaging 2007;34:487-95.
117. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 2007;32:690-5.
118. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007;48:221-6.
119. Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun 2008;29:636-41.
120. Tsakiris P, De la Rosette J. Imaging in genitourinary cancer from the urologists' perspective. Cancer Imaging 2007;7:84-92.
121. Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer 2005;15:701-9.
122. Basu S, Li G, Alavi A. PET and PET-CT imaging of gynecological malignancies: Present role and future promise. Expert Rev Anticancer Ther 2009;9:75-96.
123. Lin WC, Hung YC, Yeh LS, Kao CH, Yen RF, Shen YY. Usefulness of (18) F-fluorodeoxyglucose positron emission tomography to detect paraaortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 2003;89:73-6.
124. Belhocine T, Thille A, Fridman V, Albert A, Seidel L, Nickers P, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 2002;87:90-7. (Pubitemid 36027107)
125. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003;55:907-13.
126. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519-28.
127. Ho Shona I, Chungc D, Sawd R, Thompsond J. Imaging in cutaneous melanoma. Nucl Med Commun 2008;29:847-76.
128. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29:662-4.
129. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-Dglucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
130. Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006;93:243-9.
131. Eigtved A, Andersson AP, Dahlstrøm K, Rabøl A, Jensen M, Holm S, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-5.
132. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25:48-51.
133. Fulham M, Kelley B, Ramshaw J, Scott A. Impact of FDG PET on the management of patients with suspected or proven metastatic melanoma prior to surgery: A prospective, multi-centre study as part of the Australian PET Data Collection Project. Paper presented at: 54th Annual Meeting of the Society of Nuclear Medicine, Washington, DC. 2007.
134. Chen W, Silverman D. Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240-50.